
    
      In this phase-III trial, after due consent and completing initial 2-weeks of placebo run-in
      period with diet, exercise and counseling, eligible patients with uncontrolled T2DM will be
      randomized in balance to receive either once daily oral CPL-2009-0031 140 mg or Sitagliptin
      100 mg.

      After completing 12 weeks of study post-randomization for regulatory submission, patients
      will be instructed for continuation of extension phase of treatment and follow up upto 36
      weeks.

      HbA1c will be measured at screening, baseline, 12 weeks, 24 weeks and 36 weeks of treatment.
      While, Fasting Blood Sugar (FBS) and Postprandial Blood Sugar (PPBS) measurement will be
      performed every 2 weeks.

      The enrolled patients will be monitored for safety (AE and SAE) throughout the study period.
    
  